Ranbaxy Enters Lucrative Biosimilar Field

India's Ranbaxy - one of the world's top ten generic drug companies - has entered into an R&D agreement with compatriot firm Zenotech Laboratories for its first biosimilar, granulocyte colony-stimulating factor (G-CSF; filgrastim), which is used to prevent infections resulting from chemotherapy-induced neutropenia. BMI is encouraged by Ranbaxy's strategy as we view the biosimilar sector as the most promising segment of the pharmaceutical industry in the mid-term. Furthermore, we expect other Indian firms, such as Dr Reddy's, to follow Ranbaxy's lead given the significant upside to be realised.

To read the full article, please choose one of the following options: